FDA Grants Breakthrough Therapy Designation to Transcend Therapeutics’ TSND-201 for PTSD
Friday, July 11, 2025
Transcend Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSND-201 (methylone), an investigational treatment for Post-Traumatic Stress Disorder (PTSD). This designation is given to therapies that show the potential for significant improvement over existing treatments for serious or life-threatening conditions.
The decision was based on results from the IMPACT-1 Phase 2 clinical trial, which assessed TSND-201 in 65 individuals with severe PTSD. The study demonstrated rapid and sustained symptom improvement, with meaningful changes observed as early as Day 10 and lasting through Day 64. TSND-201 was well tolerated, with no reports of hallucinations or treatment-related discontinuations.
TSND-201 is a proprietary formulation of methylone developed by Transcend. It is a rapid-acting neuroplastogen designed to act on monoamine transporters without affecting the 5HT-2a receptor, meaning it is not hallucinogenic. The drug is currently being explored for its potential as a fast-acting and long-lasting treatment for PTSD and other central nervous system (CNS) disorders.
Post-Traumatic Stress Disorder affects around 13 million people annually in the United States, with nearly 7% of adults expected to experience the condition in their lifetime. Existing treatments, such as sertraline and paroxetine, are often slow to act and provide only modest benefits. With no new medications approved for PTSD in over two decades, there is an urgent need for more effective therapies.
The Breakthrough Therapy designation will allow Transcend to work more closely with the FDA to accelerate the development and review process for TSND-201, with the goal of advancing it to Phase 3 trials and ultimately making it available to patients in need.
Source: prnewswire.com
